# Top 200 Drugs: Endocrine, Diabetes, Metabolic, Bone, Urologic & Gastrointestinal Pharmacology

> High-yield Top 200 endocrine, metabolic, and GI medications covering insulins, metformin, GLP-1/GIP agonists, SGLT2/DPP-4 inhibitors, thyroid/adrenal hormones, osteoporosis agents, gout therapies, PPIs, antiemetics, laxatives, NSAIDs, and urologic drugs.

- **Canonical URL:** https://flashcards.world/flashcards/sets/50bf8be8-f86f-409e-a8ec-be8c9cd10ac3/
- **Markdown URL:** https://flashcards.world/flashcards/sets/50bf8be8-f86f-409e-a8ec-be8c9cd10ac3.md
- **Category:** Top 200 Prescribed Drugs (Brand, Generic, Class & MOA)
- **Level:** intermediate
- **Languages:** en → en
- **Total Cards:** 32

## Flashcards (32 Cards)

| # | Front (Term / Prompt) | Back (Definition / Answer) | Example | Multiple-Choice Options |
| :--- | :--- | :--- | :--- | :--- |
| 1 | How do Denosumab (Prolia) and Teriparatide (Forteo) differ in their mechanisms of action on bone remodeling? | Denosumab is a monoclonal antibody against RANKL, preventing osteoclast differentiation and bone resorption (safe in severe CKD; causes hypocalcemia and rebound vertebral fractures if stopped abruptly). Teriparatide is recombinant PTH (1–34) given via intermittent once-daily subcutaneous injection to stimulate osteoblasts > osteoclasts (continuous PTH causes bone resorption). |  |  |
| 2 | What is the mechanism of action of the proton pump inhibitors Omeprazole, Pantoprazole, and Esomeprazole, and what are their long-term adverse effects and CYP2C19 interaction? | Prodrugs irreversibly inhibiting the H+/K+-ATPase proton pump in gastric parietal cells (most effective taken 30 min before breakfast). Long-term risks: C. difficile infection, pneumonia, acute interstitial nephritis (AIN), hypomagnesemia, and malabsorption of vitamin B12, iron, and calcium carbonate (hip fractures). Omeprazole inhibits CYP2C19 (reducing clopidogrel activation; pantoprazole preferred). |  |  |
| 3 | What are the mechanism of action and signature adverse effects of the SGLT2 inhibitors Empagliflozin, Dapagliflozin, and Canagliflozin? | Block SGLT2 in the S1 segment of the proximal convoluted tubule, inducing glucosuria and natriuresis. Adverse effects: Genitourinary mycotic infections (vulvovaginal candidiasis), volume depletion/orthostasis, and euglycemic diabetic ketoacidosis (blood glucose often <250 mg/dL; hold 3–4 days prior to surgery). |  |  |
| 4 | What is the antidiarrheal mechanism of Loperamide and Diphenoxylate/Atropine, and why is atropine co-formulated with diphenoxylate? | Agonize peripheral mu-opioid receptors in the enteric nervous system to slow gut motility and increase fluid absorption. Loperamide is extruded from the BBB by P-glycoprotein (massive overdose causes fatal QT prolongation/Torsades). Diphenoxylate crosses the BBB at high doses and is co-formulated with subtherapeutic atropine to discourage opioid abuse via unpleasant anticholinergic effects. |  |  |
| 5 | What are the mechanisms of action and clinical indications of Ursodeoxycholic Acid (Ursodiol) and Cholestyramine? | Ursodiol is a hydrophilic bile acid that reduces biliary cholesterol secretion and protects cholangiocytes (first-line for primary biliary cholangitis, intrahepatic cholestasis of pregnancy, and radiolucent gallstone dissolution). Cholestyramine is a bile acid-binding resin used for cholestatic pruritus and bile acid diarrhea (binds digoxin, warfarin, and levothyroxine in the gut). |  |  |
| 6 | What are the mechanism of action, MASH/NASH utility, and major contraindication of Pioglitazone? | Activates nuclear PPAR-gamma transcription factor, increasing adiponectin and peripheral insulin sensitivity (and improving histological steatohepatitis in MASH/NASH). Adverse effects: Fluid retention/edema, weight gain, osteoporotic fractures, and bladder cancer; strictly contraindicated in symptomatic heart failure. |  |  |
| 7 | What are the mechanisms of action of Polyethylene Glycol, Senna, Docusate, and Lactulose, and how does Lactulose lower blood ammonia in hepatic encephalopathy? | PEG is an osmotic laxative. Senna is an anthraquinone stimulant laxative (myenteric plexus; causes benign melanosis coli). Docusate is an anionic surfactant stool softener. Lactulose is a non-absorbable disaccharide fermented by colonic bacteria into lactic/acetic acids, protonating NH3 into non-absorbable NH4+ to trap and excrete ammonia in hepatic encephalopathy. |  |  |
| 8 | What are the mechanism of action, PSA screening effect, and teratogenicity handling warning of the 5-alpha-reductase inhibitors Finasteride and Dutasteride? | Inhibit 5-alpha-reductase (finasteride blocks Type II; dutasteride blocks Types I & II), blocking conversion of testosterone to dihydrotestosterone (DHT). Shrink prostate volume in BPH (takes 3–6 months) and treat androgenetic alopecia. Decrease serum PSA by ~50% (multiply PSA by 2 when screening); pregnant women must not handle crushed tablets (male fetal ambiguous genitalia). |  |  |
| 9 | What are the calcimimetic mechanism of action and clinical indications of Cinacalcet? | Allosterically activates the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing sensitivity to extracellular Ca2+ and suppressing PTH secretion. Used for secondary hyperparathyroidism in CKD on dialysis and parathyroid carcinoma. |  |  |
| 10 | What are the mechanism, oral absorption rules, and TSH versus Free T4 monitoring rules for Levothyroxine (Synthroid)? | Synthetic T4 converted peripherally by 5'-deiodinase to active T3 (half-life ~7 days; requires 6 weeks to reach steady state). Must be taken on an empty stomach 30–60 minutes before breakfast, separated by 4 hours from calcium, iron, or PPIs. Monitored via serum TSH in primary hypothyroidism, but via free T4 in central (pituitary) hypothyroidism. |  |  |
| 11 | How do Allopurinol and Febuxostat compare with Colchicine in the management of chronic hyperuricemia versus acute gout flares? | Allopurinol and febuxostat inhibit xanthine oxidase to reduce uric acid production (chronic prophylaxis; never start or stop abruptly without anti-inflammatory prophylaxis; Both inhibit azathioprine/6-MP metabolism, causing fatal pancytopenia; screen HLA-B*58:01 for allopurinol SJS). Colchicine binds beta-tubulin to inhibit neutrophil microtubule polymerization and chemotaxis in acute gout and familial Mediterranean fever (causes severe diarrhea). |  |  |
| 12 | How do Oxybutynin and Solifenacin compare with Mirabegron in the pharmacological management of Overactive Bladder (urge incontinence)? | Oxybutynin and solifenacin are M3 muscarinic receptor antagonists that relax the detrusor muscle (adverse effects: dry mouth, constipation, urinary retention, and cognitive impairment/delirium in the elderly). Mirabegron is a beta-3 adrenergic agonist that relaxes the detrusor muscle without anticholinergic cognitive side effects (can increase blood pressure). |  |  |
| 13 | What is the mechanism of action of the DPP-4 inhibitors Sitagliptin and Linagliptin, and what is the unique renal advantage of Linagliptin? | Inhibit dipeptidyl peptidase-4, preventing breakdown of endogenous GLP-1 and GIP; weight-neutral with minimal hypoglycemia risk. Unlike sitagliptin/saxagliptin, linagliptin is cleared primarily via the hepatobiliary system and requires no renal dose adjustment at any stage of CKD. |  |  |
| 14 | How do non-selective NSAIDs (Ibuprofen, Naproxen, Ketorolac) compare with Celecoxib in COX selectivity, and what renal, GI, and cardiovascular risks do they share? | Non-selective NSAIDs reversibly inhibit COX-1 and COX-2 (decreasing prostaglandins); celecoxib selectively inhibits COX-2 (sparing GI mucosa and platelet TXA2, but tilting the PGI2/TXA2 balance toward thrombosis). All NSAIDs constrict the renal afferent arteriole (precipitating prerenal AKI, hyperkalemia, hypertension, and heart failure exacerbation; 'triple whammy' with ACEI/ARB + diuretic). |  |  |
| 15 | What are the distinct receptor targets, clinical indications, and signature side effects of Ondansetron, Metoclopramide, Scopolamine, and Aprepitant? | Ondansetron: 5-HT3 antagonist (chemo/post-op nausea; causes QTc prolongation and constipation). Metoclopramide: Central/GI D2 antagonist (prokinetic for gastroparesis and antiemetic; crosses BBB causing EPS/tardive dyskinesia; contraindicated in Parkinson disease and GI obstruction). Scopolamine: M1 antimuscarinic patch for motion sickness. Aprepitant: Central NK1 (substance P) receptor antagonist for chemotherapy-induced emesis. |  |  |
| 16 | What are the mechanism of action, glycemic/weight benefits, and renal/iodinated contrast safety rules for Metformin (Glucophage)? | Biguanide that activates hepatic AMPK and inhibits mitochondrial complex I and glycerophosphate dehydrogenase, suppressing hepatic gluconeogenesis and improving peripheral insulin sensitivity without causing hypoglycemia or weight gain (chronic use can cause vitamin B12 deficiency). Contraindicated if eGFR < 30 mL/min/1.73 m² (do not initiate if eGFR 30–45); temporarily hold metformin at the time of or prior to iodinated IV contrast procedures if eGFR is 30–60 mL/min/1.73 m² (or with liver disease, alcoholism, acute heart failure, or intra-arterial contrast) and recheck eGFR at 48 hours before restarting to prevent Metformin-Associated Lactic Acidosis (MALA). |  |  |
| 17 | How do Methimazole and Propylthiouracil (PTU) compare in antithyroid mechanisms, pregnancy trimester selection, and boxed-warning toxicities? | Both inhibit thyroid peroxidase (TPO), blocking iodide oxidation, organification, and coupling; PTU additionally inhibits peripheral 5'-deiodinase (preferred in thyroid storm and 1st trimester of pregnancy because methimazole causes aplasia cutis). Methimazole is preferred in 2nd/3rd trimesters and non-pregnant patients due to PTU's Black Box Warning for severe hepatotoxicity. Both can cause agranulocytosis (check ANC if sore throat/fever). |  |  |
| 18 | What are the mechanism of action and high-risk adverse effects of the sulfonylureas Glipizide, Glimepiride, and Glyburide? | Insulin secretagogues that bind SUR1 subunits to close ATP-sensitive K+ channels on pancreatic beta-cells, causing membrane depolarization, Ca2+ influx, and insulin release regardless of blood glucose. Cause weight gain and severe prolonged hypoglycemia (especially glyburide in elderly or renal impairment); share a sulfonamide moiety. |  |  |
| 19 | How do the Selective Estrogen Receptor Modulators (SERMs) Tamoxifen and Raloxifene differ in their tissue-specific agonist/antagonist profiles across breast, bone, and endometrium? | Tamoxifen is an ER antagonist in breast tissue (treats/prevents ER+ breast cancer) and an ER agonist in bone AND endometrium (causes endometrial hyperplasia/carcinoma). Raloxifene is an ER agonist in bone and an ER antagonist in both breast and endometrium (treats osteoporosis and reduces breast cancer risk without endometrial cancer risk). Both increase VTE risk. |  |  |
| 20 | How do Rapid-Acting (Lispro, Aspart), Short-Acting (Regular), Intermediate (NPH), and Long-Acting Basal (Glargine, Degludec) insulins compare in pharmacokinetic onset, peak, and duration? | Rapid-acting (Lispro, Aspart, Glulisine): onset 15 min, peak 1h, duration 3–4h (mealtime bolus). Short-acting (Regular): onset 30–60 min, peak 2–3h (only insulin given IV for DKA/hyperkalemia). Intermediate (NPH): peak 4–10h. Long-acting basal (Glargine, Degludec): peakless over 24+ hours. |  |  |
| 21 | How do Sucralfate and Misoprostol protect the gastric mucosa, and what are their key administration rules and contraindications? | Sucralfate (aluminum sucrose octasulfate) polymerizes in an acidic environment (requires pH < 4; do not give simultaneously with PPIs/antacids) to coat ulcer craters. Misoprostol is a PGE1 analog that increases gastric mucus/bicarbonate and decreases acid (prevents NSAID ulcers; used for medical abortion, cervical ripening, and postpartum hemorrhage; strictly contraindicated in pregnancy). |  |  |
| 22 | What is the mechanism of action of the H2 receptor antagonists Famotidine and Cimetidine, and why is Cimetidine avoided in clinical practice? | Reversibly block H2 receptors on gastric parietal cells to decrease nocturnal acid secretion. Cimetidine is avoided because it is a potent pan-CYP450 inhibitor, decreases renal creatinine secretion, and blocks androgen receptors (causing gynecomastia, impotence, and CNS confusion in older adults). |  |  |
| 23 | How do Clomiphene Citrate, Letrozole, and Leuprolide (pulsatile versus continuous) modulate the hypothalamic-pituitary-gonadal axis? | Clomiphene blocks hypothalamic estrogen receptors (eliminating negative feedback to increase GnRH/FSH/LH for ovulation induction) and Letrozole inhibits aromatase (first-line for ovulation induction in PCOS). Leuprolide is a GnRH agonist: pulsatile administration stimulates FSH/LH, whereas continuous administration downregulates pituitary GnRH receptors (chemical castration for prostate cancer, endometriosis, and uterine fibroids). |  |  |
| 24 | What are the dose-dependent mechanisms of Aspirin, why is it contraindicated in children with viral illnesses, and what acid-base disturbance characterizes salicylate toxicity? | Irreversibly acetylates COX-1 and COX-2 (low-dose 81 mg selectively blocks platelet TXA2 synthesis for the 7–10 day lifespan of the platelet). Contraindicated in children with viral illnesses due to Reye syndrome (microvesicular fatty liver + encephalopathy). Overdose causes a classic mixed acid-base disorder: early central respiratory alkalosis followed by high anion gap metabolic acidosis (tinnitus, hyperthermia; treated with IV sodium bicarbonate to alkalinize urine). |  |  |
| 25 | How do Hydrocortisone, Prednisone, and Dexamethasone compare in glucocorticoid versus mineralocorticoid potency, and what are the classic adverse effects of chronic systemic corticosteroid therapy? | Hydrocortisone (1:1 glucocorticoid:mineralocorticoid), Prednisone (4:0.8 intermediate-acting), Dexamethasone (25:0 long-acting, zero mineralocorticoid activity). Chronic systemic therapy causes iatrogenic Cushing syndrome, hyperglycemia, osteoporosis (osteoblast apoptosis), avascular necrosis of the femoral head, cataracts, peptic ulcers (with NSAIDs), neutrophilic leukocytosis (demargination), and HPA axis suppression. |  |  |
| 26 | What is the V2-receptor mechanism of Desmopressin (DDAVP), and what are its two distinct endocrine and hematologic indications? | Synthetic vasopressin analog selective for V2 receptors: (1) Inserts aquaporin-2 channels in the renal collecting duct to treat central diabetes insipidus and nocturnal enuresis; (2) Stimulates endothelial release of stored von Willebrand factor and Factor VIII to treat Type 1 vWD, mild Hemophilia A, and uremic platelet dysfunction. Adverse effect: Hyponatremia. |  |  |
| 27 | What are the mechanism of action, clinical indications, and visual side effect of the PDE-5 inhibitors Sildenafil and Tadalafil? | Inhibit phosphodiesterase-5, preventing cGMP degradation in corpus cavernosum and pulmonary arterial smooth muscle. Indications: Erectile dysfunction, pulmonary arterial hypertension (PAH), and BPH (tadalafil). Sildenafil cross-inhibits retinal PDE-6, causing transient blue-tinted vision (cyanopsia). |  |  |
| 28 | What are the mechanisms of action, cardiometabolic benefits, and contraindications of Semaglutide (Ozempic/Wegovy), Liraglutide, and Tirzepatide (Mounjaro/Zepbound)? | Semaglutide and liraglutide are GLP-1 receptor agonists; tirzepatide (Mounjaro for T2DM; Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea) is a dual GIP/GLP-1 receptor agonist. They increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote central satiety, major weight loss, and cardiovascular/renal risk reduction. Adverse effects include nausea, pancreatitis, biliary disease, and perioperative aspiration risk from delayed gastric emptying; contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2. |  |  |
| 29 | What are the mechanism of action and anatomic delivery differences between Mesalamine (5-ASA) and Sulfasalazine in Inflammatory Bowel Disease? | Topical intestinal anti-inflammatory agents (inhibit NF-kB and prostaglandins/leukotrienes) used as first-line induction and maintenance therapy in mild-to-moderate ulcerative colitis. Sulfasalazine is cleaved by colonic bacteria into active 5-ASA and sulfapyridine (which causes sulfa toxicity, reversible oligospermia, and folate deficiency). |  |  |
| 30 | What are the mechanism of action, oral administration instructions, and rare skeletal complications of the bisphosphonates Alendronate, Risedronate, and Zoledronic Acid? | Pyrophosphate analogs that bind hydroxyapatite in bone and are endocytosed by osteoclasts, inhibiting farnesyl pyrophosphate synthase and inducing osteoclast apoptosis. Oral alendronate must be taken with plain water on an empty stomach while remaining upright for >=30 minutes to prevent corrosive esophagitis. Rare complications: Osteonecrosis of the jaw (dental extractions) and atypical subtrochanteric femoral fractures. |  |  |
| 31 | What is the mechanism of action of Octreotide, and what are its four primary clinical indications? | Long-acting somatostatin analog that inhibits splanchnic blood flow and GI/pituitary hormone secretion. Indications: (1) Acute esophageal variceal bleeding, (2) Acromegaly (inhibits GH), (3) Carcinoid syndrome (flushing/diarrhea), and (4) VIPoma / gastrinoma / glucagonoma. Adverse effect: Cholelithiasis (inhibits CCK/gallbladder contractility). |  |  |
| 32 | What is the mechanism of action of Fludrocortisone, and why is it required in Primary (Addison) but not Secondary Adrenal Insufficiency? | Synthetic corticosteroid with potent mineralocorticoid (aldosterone-like) activity. Required alongside hydrocortisone in primary adrenal insufficiency (Addison disease, where the adrenal cortex including zona glomerulosa is destroyed), but NOT needed in secondary adrenal insufficiency (ACTH deficiency, where RAAS remains intact). |  |  |

---
Study this deck interactively with FSRS-6 spaced repetition, audio review, and multiple-choice mode at [Flashcards World](https://flashcards.world/flashcards/sets/50bf8be8-f86f-409e-a8ec-be8c9cd10ac3/).
